GC-101
Hepatocellular Carcinoma
PreclinicalActive
Key Facts
About Genocury Biotech
A Chinese biotech developing targeted gene therapies for oncology using advanced gene editing and delivery platforms.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Namodenoson (CF102) | Can Fite Biopharma | Phase IIb/III |
| DCR-MYC | Dicerna Pharmaceuticals | Preclinical |
| RYZ801 | RayzeBio | Preclinical |
| CT011 | CARsgen Therapeutics | Phase II |
| BRVT101 | Biorevert | Preclinical |
| BRVT121 | Biorevert | Phase I |
| BRVT151 | Biorevert | Phase I |
| HCC Diagnostic Test | Senseera | Clinical POC |
| RG6139 (RO7247669) | Chugai Pharmaceutical | Phase III |
| ALN-BCAT | Alnylam Pharmaceuticals | Phase 1 |
| HCC Program | Arcellx | Discovery |
| TTFields | Novocure | Pilot |